ASCO 2024 – Summit peaks on ivonescimab surprise
The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.
ASCO 2024 preview – more questions for BioNTech
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.
A new menin challenger
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
AACR 2024 – Transgene gets a “vaccine” boost
Early data with the group’s personalised project intrigue, but Transgene has a long road ahead.
AACR 2024 – BioNTech sees pancreatic promise amid neoantigen delays
When autogene cevumeran works it seems to keep working, but bigger tests for the project have been pushed back.
